SK180499A3 - Sertraline salts and sustained-release dosage forms of sertraline - Google Patents

Sertraline salts and sustained-release dosage forms of sertraline Download PDF

Info

Publication number
SK180499A3
SK180499A3 SK1804-99A SK180499A SK180499A3 SK 180499 A3 SK180499 A3 SK 180499A3 SK 180499 A SK180499 A SK 180499A SK 180499 A3 SK180499 A3 SK 180499A3
Authority
SK
Slovakia
Prior art keywords
sertraline
sustained release
dosage form
acetate
release dosage
Prior art date
Application number
SK1804-99A
Other languages
English (en)
Slovak (sk)
Inventor
Ende Mary Tanya Am
William John Curatalo
Hylar Lewis Friedman
Ravi Mysore Shanker
Scott Max Herbig
Dwayne Thomas Friesen
James Blair West
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SK180499A3 publication Critical patent/SK180499A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK1804-99A 1997-07-01 1998-06-15 Sertraline salts and sustained-release dosage forms of sertraline SK180499A3 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US5149897P 1997-07-01 1997-07-01
US5140297P 1997-07-01 1997-07-01
US5141497P 1997-07-01 1997-07-01
US5142097P 1997-07-01 1997-07-01
PCT/IB1998/000934 WO1999001121A1 (en) 1997-07-01 1998-06-15 Sertraline salts and sustained-release dosage forms of sertraline

Publications (1)

Publication Number Publication Date
SK180499A3 true SK180499A3 (en) 2001-08-06

Family

ID=27489408

Family Applications (1)

Application Number Title Priority Date Filing Date
SK1804-99A SK180499A3 (en) 1997-07-01 1998-06-15 Sertraline salts and sustained-release dosage forms of sertraline

Country Status (33)

Country Link
US (1) US6517866B1 (no)
EP (1) EP0999830A1 (no)
JP (1) JP2000514101A (no)
KR (2) KR100446366B1 (no)
CN (1) CN1256085C (no)
AP (1) AP1526A (no)
AR (2) AR015919A1 (no)
AU (1) AU739261B2 (no)
BG (1) BG103915A (no)
BR (1) BR9810403A (no)
CA (1) CA2290966C (no)
CO (1) CO4940402A1 (no)
DZ (1) DZ2546A1 (no)
EA (1) EA002482B1 (no)
HK (1) HK1026630A1 (no)
HR (1) HRP980379B1 (no)
HU (1) HUP0002296A3 (no)
ID (1) ID23503A (no)
IL (2) IL152330A0 (no)
IS (1) IS5265A (no)
MY (1) MY129175A (no)
NO (1) NO996518L (no)
NZ (2) NZ501251A (no)
OA (1) OA11245A (no)
PA (1) PA8454401A1 (no)
PE (1) PE88699A1 (no)
PL (1) PL337806A1 (no)
SK (1) SK180499A3 (no)
TN (1) TNSN98125A1 (no)
TR (1) TR199903280T2 (no)
TW (1) TWI241188B (no)
UY (1) UY25067A1 (no)
WO (1) WO1999001121A1 (no)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208926A1 (en) * 1997-07-01 2004-10-21 Pfizer Inc Solubilized sertraline compositions
DK1067910T3 (da) * 1998-04-03 2004-10-04 Egalet As Komposition med styret afgivelse
US6706283B1 (en) * 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
CA2698347A1 (en) * 1999-05-20 2000-11-30 Elan Pharma International Limited Multiparticulate controlled release selective serotonin reuptake inhibitor formulations
IE990406A1 (en) 1999-05-20 2000-12-27 Elan Corp Plc Multiparticulate controlled release selective serotonin reuptake inhibitor formulations.
UA75580C2 (uk) * 1999-09-03 2006-05-15 Апбі Холдінгс, Ллк Застосування дапоксетину або його фармацевтично прийнятної солі в лікарському засобі для лікування розладу статевої функції та промисловий виріб для його застосування
GB9923045D0 (en) * 1999-09-29 1999-12-01 Novartis Ag New oral formulations
WO2001047498A2 (en) * 1999-12-23 2001-07-05 Pfizer Products Inc. Hydrogel-driven layered drug dosage form comprising sertraline
US6620431B1 (en) * 2000-04-17 2003-09-16 Charles Signorino Shellac film coatings providing release at selected pH and method
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2420535A1 (en) 2000-08-30 2002-03-07 Mary Tanya Am Ende Sustained release formulations for growth hormone secretagogues
US6482440B2 (en) * 2000-09-21 2002-11-19 Phase 2 Discovery, Inc. Long acting antidepressant microparticles
SE0004671D0 (sv) 2000-12-15 2000-12-15 Amarin Dev Ab Pharmaceutical formulation
JP2002212062A (ja) * 2001-01-24 2002-07-31 Teijin Ltd 遅延放出制御組成物
CN1204922C (zh) * 2001-02-15 2005-06-08 株式会社三和化学研究所 新的眼科用组合物
CA2444569C (en) * 2001-04-18 2011-01-04 Nostrum Pharmaceuticals Inc. A novel coating for a sustained release pharmaceutical composition
JP2004536855A (ja) * 2001-07-16 2004-12-09 アストラゼネカ・アクチエボラーグ プロトンポンプ阻害剤および酸中和剤を含む医薬製剤
WO2003024430A1 (en) 2001-09-21 2003-03-27 Egalet A/S Morphine polymer release system
EP1429739A1 (en) * 2001-09-21 2004-06-23 Egalet A/S Polymer release system
ES2311073T3 (es) * 2001-09-28 2009-02-01 Mcneil-Ppc, Inc. Forma de dosificacion que tiene un nucleo interno y un revestimiento externo.
US7005138B2 (en) * 2001-12-21 2006-02-28 Duramed Pharmaceuticals, Inc. Method of systematically delivering SSRIs
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
US20100189797A1 (en) 2002-06-10 2010-07-29 Julien Mendlewicz Oral antidepressant formulation
US20050226926A1 (en) * 2002-07-25 2005-10-13 Pfizer Inc Sustained-release tablet composition of pramipexole
AU2003272461A1 (en) * 2002-09-16 2004-04-30 Sepracor Inc. TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE
US20040220153A1 (en) * 2002-09-24 2004-11-04 Jost-Price Edward Roydon Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines
CA2415154C (en) * 2002-12-24 2009-06-16 Biovail Laboratories Inc. Modified release formulations of selective serotonin re-uptake inhibitors
WO2004065348A1 (en) * 2003-01-23 2004-08-05 Pfizer Products Inc. Pharmaceutically acceptable salts of sertraline and pharmaceutical compositions thereof
EP1599212A4 (en) * 2003-02-14 2006-02-08 Combinatorx Inc POLYTHERAPY FOR THE TREATMENT OF IMMUNO-INFLAMMATORY DISORDERS
WO2004084868A1 (en) * 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
JP2006522099A (ja) * 2003-04-04 2006-09-28 ファルマシア コーポレーション 複合粒状体からなる経口徐放性圧縮錠
DK1631251T3 (da) 2003-04-24 2011-10-03 Jagotec Ag Tablet til forsinket frigørelse med defineret kernegeometri
EP1626950A4 (en) * 2003-05-23 2007-05-23 Transform Pharmaceuticals Inc SERTRALINZUSAMMENSETZUNGEN
PL196544B1 (pl) * 2003-08-08 2008-01-31 Biovail Lab Int Srl Tabletka o zmodyfikowanym uwalnianiu
US7893300B2 (en) * 2003-11-04 2011-02-22 Cipla Limited Process for the preparation of polymorphs of selective serotonin reuptake inhibitor
TW201240679A (en) * 2004-03-12 2012-10-16 Capsugel Belgium Nv Pharmaceutical formulations
KR100772980B1 (ko) * 2004-04-01 2007-11-02 한미약품 주식회사 메트포르민의 경구투여용 서방성 제제
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
ITMI20041295A1 (it) * 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
CA2572864C (en) 2004-08-13 2014-02-11 Boehringer Ingelheim International Gmbh Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof, method for manufacturing the same and use thereof
KR100920856B1 (ko) * 2004-11-30 2009-10-09 (주)아모레퍼시픽 선택적 세로토닌 재흡수 억제제의 연장방출 제제 및 그제조방법
WO2006072878A1 (en) * 2005-01-07 2006-07-13 Ranbaxy Laboratories Limited Oral dosage forms of sertraline having controlled particle size and processes for their preparation
US20080274183A1 (en) * 2005-02-04 2008-11-06 Phillip Michael Cook Thermoplastic articles containing a medicament
CA2601800C (en) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Oral drug delivery system
NZ563846A (en) * 2005-06-03 2010-03-26 Egalet As A drug delivery system for delivering active substances dispersed in a dispersion medium
US8747897B2 (en) * 2006-04-27 2014-06-10 Supernus Pharmaceuticals, Inc. Osmotic drug delivery system
US7893053B2 (en) * 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
MY149863A (en) 2006-08-03 2013-10-31 Nitec Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
AU2008207200B2 (en) * 2007-01-16 2011-02-17 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008148798A2 (en) 2007-06-04 2008-12-11 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
WO2009034431A2 (en) 2007-09-10 2009-03-19 Pfizer Inc. Controlled-release dosage forms for varenicline
NZ592765A (en) * 2008-08-14 2013-06-28 Bioneer As Tablets with a coating which impedes the release of an active ingredient
DE102008051572A1 (de) 2008-09-05 2010-03-11 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Herstellung von Phosphatbindern und auf diese Weise hergestellte Phosphatbinder
AU2008243202B2 (en) * 2008-11-11 2015-08-20 Cosmo Technologies Ltd Oral antimicrobial pharmaceutical compositions
US9005660B2 (en) 2009-02-06 2015-04-14 Egalet Ltd. Immediate release composition resistant to abuse by intake of alcohol
CA2766179A1 (en) 2009-06-24 2010-12-29 Egalet Ltd. Controlled release formulations
JP2013509963A (ja) 2009-11-09 2013-03-21 スポットライト テクノロジー パートナーズ エルエルシー 断片化ヒドロゲル
EP2498763A4 (en) 2009-11-09 2015-10-07 Spotlight Technology Partners Llc HYDROGELS BASED ON POLYSACCHARIDE
EP2877161A1 (en) 2012-07-06 2015-06-03 Egalet Ltd. Abuse deterrent pharmaceutical compositions for controlled release
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
WO2016020936A2 (en) * 2014-07-21 2016-02-11 Patel Jayendrakumar Dasharathlal A novel oral gastroretentive pharmaceutical dosage form
CN104402705B (zh) * 2014-11-04 2017-04-12 成都理工大学 球形柠檬酸钙及其制备方法和应用
JP6455293B2 (ja) * 2015-04-21 2019-01-23 ニプロ株式会社 セルトラリン及び／又はその薬学上許容しうる塩を含む製剤
KR20200071085A (ko) * 2017-10-05 2020-06-18 푸락 바이오켐 비.브이. 락테이트 분말 및 이의 제조방법
CN109432038A (zh) * 2018-12-28 2019-03-08 乐普制药科技有限公司 一种含有盐酸舍曲林的肠溶片剂及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536518A (en) 1979-11-01 1985-08-20 Pfizer Inc. Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine
DK150008C (da) 1981-11-20 1987-05-25 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk oralt polydepotpraeparat
US4847092A (en) 1985-11-12 1989-07-11 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US4797286A (en) 1985-11-12 1989-01-10 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulations
US5112619A (en) 1985-11-12 1992-05-12 Eli Lilly And Company Orally administerable sustained release pharmaceutical formulation
US4803076A (en) * 1986-09-04 1989-02-07 Pfizer Inc. Controlled release device for an active substance
DE3700420A1 (de) * 1986-12-22 1988-07-07 Efka Werke Kiehn Gmbh Fritz Tabakerzeugnis fuer die selbstverfertigung einer zigarette, insbesondere filter-zigarette
US5135947A (en) 1987-04-09 1992-08-04 Eli Lilly And Company 1-phenyl-3-naphthalenyloxypropanamines and their use as selective serotonin reuptake inhibitors
US4777288A (en) 1987-06-11 1988-10-11 Pfizer Inc. Process for preparing a 4,4-diphenylbutanoic acid derivative
US4839104A (en) 1987-06-11 1989-06-13 Pfizer, Inc. Process for preparing sertraline intermediates
US4792448A (en) 1987-06-11 1988-12-20 Pfizer Inc. Generic zero order controlled drug delivery system
US4971998A (en) 1987-10-22 1990-11-20 Massachusetts Institute Of Technology Methods for treating the premenstrual or late luteal phase syndrome
US4876282A (en) 1987-11-25 1989-10-24 Eli Lilly And Company 1-Phenylalkylamines as selective serotonin uptake inhibitors
US4855500A (en) 1988-05-04 1989-08-08 Pfizer Inc. Process for preparing a ketimine
US5026707A (en) 1988-05-23 1991-06-25 Eli Lilly And Company Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes
IL91398A (en) 1988-08-30 1994-05-30 Pfizer A device for the controlled release of pneumatic substances, including the active substance, surrounded by an asymmetric membrane
ZA901277B (en) 1989-02-27 1991-10-30 Lilly Co Eli Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes and 3-aminochromanes
US4981870A (en) 1989-03-07 1991-01-01 Pfizer Inc. Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants
US4983401A (en) 1989-05-22 1991-01-08 Kinaform Technology, Inc. Sustained release pharmaceutical preparations having pH controlled membrane coatings
EP0415612B1 (en) 1989-08-30 1993-11-10 Pfizer Inc. Use of sertraline for the treatment of chemical dependencies
US5130338A (en) 1989-08-30 1992-07-14 Pfizer Inc. Method of treating chemical dependencies using sertraline
US4940731A (en) 1989-08-30 1990-07-10 Pfizer Inc. Method of treating premature ejaculation using sertraline
US4962128A (en) 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
WO1992000103A1 (en) 1990-06-28 1992-01-09 Beecham Group Plc Pharmaceutical preparations
ATE118345T1 (de) 1990-08-07 1995-03-15 Pfizer Verwendung von interfacial polymerisierten membranen in abgabevorrichtungen.
PT98628A (pt) 1990-08-09 1992-06-30 Massachusetts Inst Technology Processo de composicoes farmaceuticas a base de por exemplo sertralina
US5104899A (en) 1990-08-13 1992-04-14 Sepracor, Inc. Methods and compositions for treating depression using optically pure fluoxetine
JPH06502854A (ja) 1990-11-24 1994-03-31 ビーチャム・グループ・パブリック・リミテッド・カンパニー 老年痴呆、過食症、片頭痛または食欲不振の治療用のパロキセチンの使用
DK0498590T3 (da) 1991-02-08 1997-05-05 Lilly Co Eli Ringsubstituerede 2-amino-1,2,3,4-tetrahydronaphthalener
WO1992018005A1 (en) 1991-04-16 1992-10-29 National Institutes Of Health Method of treating trichotillomania and onychophagia
US5196607A (en) 1992-02-14 1993-03-23 Pfizer Inc. Process for preparing ketone enantiomer
AU668386B2 (en) 1992-03-25 1996-05-02 Depomed Systems, Incorporated Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5518730A (en) 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
US5248699A (en) 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
US6440457B1 (en) 1993-05-27 2002-08-27 Alza Corporation Method of administering antidepressant dosage form
IE930485A1 (en) 1993-06-28 1994-12-28 Hemisphere Ltd Antidepressant agents with a rapid onset of action
US5597826A (en) 1994-09-14 1997-01-28 Pfizer Inc. Compositions containing sertraline and a 5-HT1D receptor agonist or antagonist
CA2197554A1 (en) 1994-09-19 1996-03-28 The Du Pont Merck Pharmaceutical Company Combination of an opioid antagonist and a selective serotonin reuptake inhibitor for treatment of alcoholism and alcohol dependence
DK0768083T3 (da) 1995-07-17 2003-06-23 Pfizer Anvendelse af sertralin til at behandle patienter med post myocardisk infarkt
GB9514842D0 (en) 1995-07-20 1995-09-20 Smithkline Beecham Plc Novel formulation
IL126203A (en) 1996-03-25 2002-12-01 Lilly Co Eli A synergistic painkiller that contains olenzapine and another painkiller
ZA97976B (en) * 1996-04-05 1997-08-18 Alza Corp Uniform drug delivery theraphy.
US5741807A (en) 1996-09-27 1998-04-21 Cytos Pharmaceuticals, L.P. Histidine compositions and methods for treating or preventing infectious and non-infectious diarrheas
US6590083B1 (en) 1999-04-16 2003-07-08 Ortho-Mcneil Pharmaceutical, Inc. Ketolide antibacterials

Also Published As

Publication number Publication date
BG103915A (en) 2000-07-31
KR100446366B1 (ko) 2004-09-01
AR065827A2 (es) 2009-07-08
ID23503A (id) 2000-04-27
JP2000514101A (ja) 2000-10-24
NZ513456A (en) 2003-02-28
IS5265A (is) 1999-11-23
HK1026630A1 (en) 2000-12-22
DZ2546A1 (fr) 2003-02-08
TNSN98125A1 (fr) 2005-03-15
EA002482B1 (ru) 2002-06-27
CA2290966A1 (en) 1999-01-14
KR100412327B1 (ko) 2003-12-31
AR015919A1 (es) 2001-05-30
PE88699A1 (es) 1999-09-20
HRP980379A2 (en) 1999-04-30
IL152330A0 (en) 2003-05-29
CO4940402A1 (es) 2000-07-24
AP1526A (en) 2006-01-03
AU739261B2 (en) 2001-10-11
HUP0002296A2 (hu) 2001-10-28
EA199900964A1 (ru) 2000-08-28
UY25067A1 (es) 2000-12-29
KR20010014043A (ko) 2001-02-26
BR9810403A (pt) 2000-08-29
EP0999830A1 (en) 2000-05-17
MY129175A (en) 2007-03-30
HRP980379B1 (en) 2003-04-30
NO996518D0 (no) 1999-12-28
CA2290966C (en) 2005-12-20
OA11245A (en) 2003-07-23
NO996518L (no) 2000-02-29
KR20040004367A (ko) 2004-01-13
NZ501251A (en) 2001-09-28
CN1256085C (zh) 2006-05-17
IL133080A0 (en) 2001-03-19
CN1261793A (zh) 2000-08-02
PA8454401A1 (es) 2000-05-24
TWI241188B (en) 2005-10-11
AU7544998A (en) 1999-01-25
TR199903280T2 (xx) 2000-11-21
US6517866B1 (en) 2003-02-11
HUP0002296A3 (en) 2001-11-28
WO1999001121A1 (en) 1999-01-14
AP9801281A0 (en) 1998-06-30
PL337806A1 (en) 2000-09-11

Similar Documents

Publication Publication Date Title
US6517866B1 (en) Sertraline salts and sustained-release dosage forms of sertraline
Sungthongjeen et al. Design and evaluation of floating multi-layer coated tablets based on gas formation
US5891474A (en) Time-specific controlled release dosage formulations and method of preparing same
KR101774676B1 (ko) 히드로모르폰 및 날록손을 포함하는 제약 조성물
CA2850468C (en) Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract
KR19990021897A (ko) 경구용 고형 제형
US6468560B2 (en) Controlled release dosage form of [R-(Z)]-α-(methoxyimino)-α-(1-azabicyclo[2.2.2]oct-3yl) acetonitrile monohydrochloride
JP2005512997A (ja) タムスロシン錠
WO2010079221A1 (en) Pharmaceutical composition comprising one or more fumaric acid esters
US20130004545A1 (en) Slow release pharmaceutical compositions of iloperidone
KR20110033262A (ko) 이식 환자의 개선된 치료를 위한 타크로리무스
KR100369698B1 (ko) 서트랄린의 지연-방출성 투여 형태
WO2006005512A1 (en) Granules for controlled release of tamsulosin
AU742535B2 (en) Solubilized sertraline compositions
AU761618B2 (en) Sertraline salts and sustained-release dosage forms of sertraline
WO2006076951A1 (en) Pharmaceutical polymer composition for oral controlled-release delivery of terbutaline sulfate
EP1736150A2 (en) Sertraline salts and sustained-release dosage forms of sertraline
CZ9904640A3 (cs) Soli sertralinu a dávkovači formy sertralinu s vytrvalým uvolňováním sertralinu
EP1558222A2 (en) Pharmaceutical compositions containing venlafaxine
MXPA99012082A (en) Delayed-release dosage forms of sertraline